8-K: Lifecore Biomedical Secures $24.3 Million in Private Placement, Reports Q1 Fiscal 2025 Results

Lifecore Biomedical closed a $24.3 million private placement and reported first quarter fiscal 2025 financial results, highlighting increased capacity and new customer agreements.

Summary

• Lifecore Biomedical secured approximately $24.3 million through a private placement of 5,928,775 shares of common stock at $4.10 per share.
• The company's first quarter fiscal 2025 revenue was $24.7 million, a slight increase from $24.5 million in the same period last year.
• Gross profit for the quarter was $5.4 million, up from $2.7 million year-over-year, due to a favorable sales mix and price increases.
• Selling, general, and administrative expenses increased to $14.8 million, primarily due to higher professional fees and stock-based compensation.
• The net loss for the quarter was $16.2 million, or $0.53 per diluted share, compared to a net loss of $10.8 million, or $0.35 per diluted share, in the prior year.
• Adjusted EBITDA for the quarter was $(1.8) million, consistent with the $(2.0) million in the prior year period.
• Lifecore reaffirmed its fiscal year 2025 guidance, projecting revenue between $126.5 million and $130 million and Adjusted EBITDA between $19 million and $21 million.
• The company has more than doubled its capacity with the installation of a new 5-head isolator filler, increasing potential annual revenue to approximately $300 million.
• Lifecore signed four new customer agreements and several expansion agreements with existing customers during the quarter.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has made significant progress in expanding capacity, securing new customers, and raising capital, the increased net loss and expenses are concerning. The reaffirmation of guidance and positive future outlook provide some optimism, but the financial results temper the overall sentiment.

Positives

• The successful private placement provides financial stability for the company's growth plans.
• The new 5-head isolator filler significantly increases manufacturing capacity and revenue potential.
• The company is actively expanding its customer base and project pipeline.
• Lifecore has reaffirmed its financial guidance for fiscal year 2025.
• The company has regained compliance with Nasdaq listing requirements, removing a potential delisting risk.

Negatives

• The company reported a net loss of $16.2 million for the quarter.
• Selling, general, and administrative expenses increased significantly due to higher professional fees and stock-based compensation.
• Interest expense increased due to the amortization of the debt discount on the Alcon term loan facility.
• CDMO revenues decreased by $1.3 million due to one customer working down inventory levels.

Risks

• The company's financial results are subject to market forces, customer order timing, and the success of new business development.
• The company's ability to achieve its financial guidance depends on its ability to grow and diversify its new business development revenue.
• The company's financial performance is subject to the risks and uncertainties outlined in its SEC filings.
• The company is subject to the risk of not being able to maintain compliance with Nasdaq listing standards.

Future Outlook

Lifecore has established medium-term financial objectives targeting double-digit revenue CAGR and Adjusted EBITDA margins in line with peers, with further details to be discussed at a future Investors Day in November. The company is reaffirming its fiscal year 2025 guidance for both revenue and Adjusted EBITDA.

Management Comments

• Paul Josephs, president & chief executive officer of Lifecore, stated that the company's operational and business development achievements supported its growth strategy.
• Management believes the recent financing, along with other potential non-dilutive actions, will provide the financial stability needed to focus on growing the business aggressively.
• Management is optimistic about the opportunity ahead and believes the company has strengthened its potential for sustainable growth.

Industry Context

The announcement aligns with the broader trend of growth in the CDMO market, particularly in the sterile injectables segment. The company's focus on expanding capacity and securing new customer agreements positions it to capitalize on this growth.

Comparison to Industry Standards

• Lifecore's focus on sterile injectables aligns with the fastest-growing segment of the CDMO market, which is projected to increase by 100% by 2030.
• The company's new 5-head isolator filler positions it to compete with other CDMOs offering advanced fill/finish capabilities, such as Catalent and Lonza.
• The company's medium-term financial objectives of double-digit revenue CAGR and Adjusted EBITDA margins in line with peers are consistent with the goals of other publicly traded CDMOs.
• The company's focus on complex formulations, including biologics, GLP-1s, and monoclonal antibodies, targets a high-value segment of the market, similar to other specialized CDMOs.

Related Party Transactions

• Certain Purchasers in the private placement are affiliated with members of the company's board of directors, as described in the company's definitive proxy statement filed on September 23, 2024.

Stakeholder Impact

• Shareholders: The private placement provides financial stability but also dilutes existing shares. The company's growth strategy and reaffirmed guidance are positive for long-term value.
• Employees: The company's growth plans and new leadership team may provide opportunities for career advancement.
• Customers: The expanded capacity and capabilities of the company may lead to improved service and product offerings.
• Suppliers: The company's growth may lead to increased demand for their products and services.
• Creditors: The private placement improves the company's financial position and reduces the risk of default.

Next Steps

• The company will prepare and file a resale registration statement with the SEC to register the resale of the shares issued in the private placement.
• The company will continue to execute its growth strategy, focusing on maximizing its existing business, advancing its development pipeline, and pursuing new business opportunities.
• The company plans to discuss its medium-term financial objectives in more detail at its future Investors Day in November.

Key Dates

Keywords

CDMO, contract manufacturing, private placement, sterile injectables, hyaluronic acid, biologics, pharmaceuticals, manufacturing capacity, financial results, revenue, EBITDA